Aortic GAGs, Aortic Glycosaminoglycans, Glycosaminoglycans, Glycosaminoglycanes, Glycosaminoglycannes, Heparinoid Fraction, Heparinoids, Héparinoïdes, Mesoglicano, Mésoglycane, Mucopolysaccharide, Sulfomucopolysaccharide.
Mesoglycan is a substance obtained from cow lung or cow blood vessel (aorta) or pig intestine. It is used as medicine for various blood vessel disorders. Depending on the use, mesoglycan is taken by mouth, or applied to the skin, or given by injection into the muscle (intramuscularly) or the bloodstream (intravenously, by IV).
Mesoglycan is used for treating “hardening of the arteries” (atherosclerosis); hemorrhoids; swelling (inflammation) of the blood vessels (vasculitis); poor blood circulation that can lead to varicose veins and other blood vessel problems; leg ulcers; high blood fat levels, especially high triglycerides; and stroke.
It is also used for reducing leg pain during walking that is often experienced by people with peripheral artery disease (PAD).
Mesoglycan is sometimes used to improve thinking skills in people with poor blood circulation in the brain.
Another use is prevention of blood clots in the legs (deep venous thrombosis, DVT).
Mesoglycan is sometimes applied directly to the skin for treating leg ulcers.
Healthcare providers give mesoglycan as a shot to treat poor blood circulation, leg ulcers, heart disease, and stroke. They give it intravenously to treat lower limb ischemia, a condition in which enough oxygen doesn't get to the tissues in the legs because of blood vessel problems.
How does it work?
Mesoglycan appears to have effects that improve blood flow and reduce the risk of clotting.
Possibly Effective for...
- Improving thinking and quality of life in people with limited blood flow to the brain. Taking mesoglycan by mouth seems to improve oxygenation of the brain and quality of life when used over a 6-month period. There is some evidence that mesoglycan might work about as well as standard treatment with medications that thin the blood.
- High levels of blood fats called triglycerides. Taking mesoglycan by mouth seems to reduce total and very low-density lipoprotein (VLDL) triglycerides in people with high blood levels of triglycerides.
- Reducing pain when walking in people with a disease called peripheral arterial disease. Alternating intravenous and oral mesoglycan seems to improve walking distance in patients with leg pain due to peripheral arterial disease. Also, giving mesoglycan as a shot for 3 weeks then taking mesoglycan by mouth for 20 weeks seems to improve walking distance in these patients. However, taking mesoglycan by mouth seems to be less effective for improving walking distance than taking the drug defibrotide.
- Treating poor circulation that can lead to varicose veins and other conditions. There is some evidence giving mesoglycan by mouth or as an injection may improve the symptoms associated with various vein conditions, including varicose veins and swollen veins (phlebitis), when used over a 1-3 month period. Applying mesoglycan directly to the skin also seems to be helpful for treating leg ulcers in people with poor circulation.
- Treating leg ulcers. Administering a combination of mesoglycan, given by mouth and as a shot, seems to boost the effectiveness of usual treatment for leg ulcers.
Possibly Ineffective for...
- Blood clots that form in veins deep in the body (deep vein thrombosis, DVT). Taking mesoglycan by mouth along with using compression stockings after standard DVT therapy does not seem to help prevent DVT from recurring.
- Stroke. Giving mesoglycan as a shot and injecting dexamethasone intravenously (by IV) for 5 days after a stroke, then taking mesoglycan by mouth for another 25 days, does not seem to improve outcomes for people who have had a stroke.
Insufficient Evidence to Rate Effectiveness for...
- “Hardening of the arteries” (atherosclerosis). There is some early evidence that mesoglycan might slow the progression of atherosclerosis by keeping blood vessel walls from thickening.
- Swelling (inflammation) of blood vessels (vasculitis). There is some developing evidence that mesoglycan given as a shot might be useful for treating some people with this condition.
- Other conditions.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Mesoglycan is POSSIBLY SAFE for most adults when taken by mouth. It can cause nausea, vomiting, heartburn, headache, diarrhea, and skin reactions.
Because mesoglycan comes from animal products, there is a risk that diseases could be accidentally transmitted from sick animals.
There isn't enough information to know whether mesoglycan is safe when used applied to the skin or given intravenously (by IV).
Bleeding disorders: Mesoglycan might cause bleeding in people with clotting problems. Use with caution.
An allergy to the blood thinner heparin: Mesoglycan might cause allergic reactions in people who are allergic to heparin or related drugs.
Surgery: Mesoglycan might slow blood clotting. There is some concern that it might cause extra bleeding if used near the time of surgery. Stop using mesoglycan at least 2 weeks before a scheduled surgery.
Medications for dissolving blood clots (Thrombolytic drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Mesoglycan decreases blood clotting. Taking mesoglycan with medications used for dissolving blood clots might increase the chance of bleeding and bruising.
Some medications used for dissolving blood clots include alteplase (Activase), anistreplase (Eminase), reteplase (Retevase), streptokinase (Streptase), and urokinase (Abbokinase).
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Mesoglycan might slow blood clotting. Taking mesoglycan along with medications that also slow clotting might increase the chances of bruising and bleeding.
Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.
The following doses have been studied in scientific research:
- For preventing disorders of blood flow to the brain: mesoglycan 100-144 mg per day.
- For high triglycerides: mesoglycan 96 mg per day.
- For poor blood circulation: 50 mg three times daily.
- Healthcare providers give mesoglycan shots to treat cerebrovascular disease, poor blood circulation, and ulcers caused by poor circulation.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Bettini, R., Maino, C., and Gorini, M. [Effectiveness of mesoglycan in the prevention of cerebral ischemia]. Clin.Ter. 2003;154(1):13-16. View abstract.
Eisenstein, R., Goren, S. B., Shumacher, B., and Choromokos, E. The inhibition of corneal vascularization with aortic extracts in rabbits. Am J Ophthalmol. 1979;88(6):1005-1012. View abstract.
Eisenstein, R., Schumacher, B., Meineke, C., Matijevitch, B., and Kuettner, K. E. Growth regulators in connective tissue. Systemic administration of an aortic extract inhibits tumor growth in mice. Am J Pathol. 1978;91(1):1-9. View abstract.
Gaton, E., Ben Ishay, D., and Wolman, M. Experimentally produced hypertension and aortic acid esterase. Arch Pathol Lab Med 1976;100(10):527-530. View abstract.
Giorgetti, P. L., Marenghi, M. C., and Bianciardi, P. [Heparan sulfate in the therapy of postphlebitic syndrome. Evaluation of the efficacy and tolerability as compared to mesoglycan]. Minerva Cardioangiol. 1997;45(6):279-284. View abstract.
Ho, K. J., Forestner, J. E., and Manalo-Estrella, P. Aortic acid mucopolysaccharides: changes during pregnancy, enovid-treatment, and hypercholesteremia in rabbits. Proc Soc Exp Biol Med 1971;137(1):10-12. View abstract.
Hunt, C. E., Landesman, J., and Newberne, P. M. Copper deficiency in chicks: Effects of ascorbic acid on iron, copper, cytochrome oxidase activity, and aortic mucopolysaccharides 1; . British Journal of Nutrition 1970;24(3):607-614.
Kobayashi, T., Osakabe, T., and Seyama, Y. Comparison of elastolytic activity between experimental aneurysm and experimental diabetes mellitus. Biol Pharm Bull. 1998;21(7):775-777. View abstract.
Laurora, G., Ambrosoli, L., Cesarone, M. R., De Sanctis, M. T., Incandela, L., Marelli, C., and Belcaro, G. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994;36(2):83-86. View abstract.
Laurora, G., Cesarone, M. R., De Sanctis, M. T., Incandela, L., and Belcaro, G. Delayed arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. J.Cardiovasc.Surg.(Torino) 1993;34(4):313-318. View abstract.
Lewis, C. J. Letter to Reiterate Certain Public Health and Safety Concerns to Firms Manufacturing or Importing Dietary Supplements that Contain Specific Bovine Tissues. 11-14-2000;
Mansi, D., Sinisi, L., De Michele, G., Di Geronimo, G., Palma, V., Brescia, Morra, V, Coppola, N., and Buscaino, G. A. Open trial of mesoglycan in the treatment of cerebrovascular ischemic disease. Acta Neurol.(Napoli) 1988;10(2):108-112. View abstract.
Messa, G., Blardi, P., La Placa, G., Puccetti, L., and Ghezzi, A. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study]. Recenti Prog.Med. 1995;86(7-8):272-281. View abstract.
Mourao, P. A. and Bracamonte, C. A. The binding of human aortic glycosaminoglycans and proteoglycans to plasma low density lipoproteins. Atherosclerosis 1984;50(2):133-146. View abstract.
Nakamura, T., Tokita, K., Tateno, S., Kotoku, T., and Ohba, T. Human aortic acid mucopolysaccharides and glycoproteins. Changes during ageing and in atherosclerosis. J Atheroscler.Res 1968;8(6):891-902. View abstract.
Nenci, G. G., Gresele, P., Ferrari, G., Santoro, L., and Gianese, F. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb.Haemost. 2001;86(5):1181-1187. View abstract.
Rabinowitz, S. G., Eisenstein, R., and Huprikar, J. Aorta contains extractable immunosuppressant activity. J Lab Clin Med 1980;95(4):485-496. View abstract.
Rymaszewski, Z., Sprinkle, D. J., Yunker, R. L., Stevens, C. A., and Subbiah, M. T. Cholestyramine treatment in early life. Immediate and delayed effects on arterial cholesteryl ester metabolizing enzymes in the rabbit. Atherosclerosis 1987;63(1):27-32. View abstract.
Simon, J. S., Brody, M. J., and Kasson, B. G. Characterization of a vasopressin-like peptide in rat and bovine blood vessels. Am J Physiol 1992;262(3 Pt 2):H799-H805. View abstract.
Tardieu, M., Bourin, M. C., Desgranges, P., Barbier, P., Barritault, D., and Caruelle, J. P. Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs). Growth Factors 1994;11(4):291-300. View abstract.
Tovar, A. M., Cesar, D. C., Leta, G. C., and Mourao, P. A. Age-related changes in populations of aortic glycosaminoglycans: species with low affinity for plasma low-density lipoproteins, and not species with high affinity, are preferentially affected. Arterioscler.Thromb.Vasc.Biol. 1998;18(4):604-614. View abstract.
Vecchio, F., Zanchin, G., Maggioni, F., Santambrogio, C., and De Zanche, L. Mesoglycan in treatment of patients with cerebral ischemia: effects on hemorheologic and hematochemical parameters. Acta Neurol.(Napoli) 1993;15(6):449-456. View abstract.
Abate G, Berenga A, Caione F, et al. [Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease]. Minerva Med 1991;82:101-5. View abstract.
Agrati AM, De Bartolo G, Palmieri G. [Heparan sulfate: efficacy and safety in patients with chronic venous insufficiency]. Minerva Cardioangiol 1991;39:395-400. View abstract.
Ambrosio LA, Marchese G, Filippo A, et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993;21:138-46. View abstract.
Andreozzi GM, Signorelli S, Lo Duca S, et al. Effects of mesoglycan sulfate on the arterial elastic module. Angiology 1987;38:593-600. View abstract.
Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001;22:365-72. View abstract.
Blardi P, Messa G, Puccetti L, et al. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man]. Recenti Prog Med 1995;86:282-9. View abstract.
Cazzato G, Zorzon M, Mase G, et al. [Mesoglycan in acute focal cerebral ischemia]. Riv Neurol 1989;59:121-6. View abstract.
La Marca G, Pumilia G, Martino A. [Effectiveness of mesoglycan topical treatment of leg ulcers in subjects with chronic venous insufficiency]. Minerva Cardioangiol 1999;47:315-9. View abstract.
Laurora G, Cesarone MR, Belcaro G, et al. [Control of the progress of arteriosclerosis in high risk subjects treated with mesoglycan. Measuring the intima media]. Minerva Cardioangiol 1998;46:41-7. View abstract.
Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. Int J Dermatol 1993;32:368-71. View abstract.
Murray MT. Encyclopedia of Nutritional Supplements. Rocklin, CA: Prima Health, 1996.
Orlandi G, Viapiano F, Massetani R, et al. Clinical-instrumental evaluation of the effects of mesoglycan sulphate in chronic vascular encephalopathy. Acta Neurol (Napoli) 1991;13:255-60. View abstract.
Petruzzellis V, Velon A. [Therapeutic action of oral mesoglycan in the pharmacologic treatment of the varicose syndrome and its complications]. Minerva Med 1985;76:543-8. View abstract.
Postiglione A, De Simone B, Rubba P, et al. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia. Pharmacol Res Commun 1984;16:1-8. View abstract.
Prandoni P, Cattelan AM, Carta M. [Long-term sequelae of deep venous thrombosis of the legs. Experience with mesoglycan]. Ann Ital Med Int 1989;4:378-85. View abstract.
Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92. View abstract.
Scondotto G, Catena G, Aloisi D. [Use of mesoglycan in venous pathology]. Minerva Med 1997;88:537-41. View abstract.
Scondotto G, De Fabritiis A, Guastarobba A, et al. [Use of a minor fibrinolytic drug (mesoglycan) in phlebitis]. Minerva Med 1984;75:1733-8. View abstract.
Vecchio F, Zanchin G, Maggioni F, et al. Mesoglycan in treatment of patients with cerebral ischemia: effects on hemorheologic and hematochemical parameters. Acta Neurol (Napoli) 1993;15:449-56.
Vittoria A, Messa GL, Frigerio C, et al. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tissue React 1988;10:261-6. View abstract.